The University of Kansas Cancer Center (KUCC) is a matrix cancer center that includes: the University of Kansas Medical Center campuses in Kansas City and Wichita, the University of Kansas-Lawrence, and the Stowers Institute for Medical Research (via consortium agreement). In 2010, 143 members of KUCC accounted for $11.4 million of NCI funding and a total of $55.1 million in overall cancer-related funding. KUCC is led by Roy A. Jensen, M.D. who is supported by a strong, nationally recognized leadership team. Over the last seven years substantial progress has been made securing institutional commitment, recruiting key leadership positions, building nationally significant research programs, developing our clinical research program, improving and expanding our facilities, and creating transdisciplinary and collaborative interactions. With input from our External Advisory Board, we have established three goals for KUCC that will insure we make a national impact in the fight against cancer: Goal 1: Become the leading academic institution for transforming discoveries from the laboratory into new anticancer drug therapies. Goal 2: Provide the optimal environment for basic, translational, clinical, and population-based research in oncology by developing and fostering a collaborative, collegial, and dynamic culture of scientific inquiry. Goal 3: Be a nationally recognized leader in partnering with community oncologists and other key stakeholders to develop, promote, and foster the adoption and implementation of research-based cancer prevention, diagnosis, treatment, control, and survivorship practices throughout our service area. To accomplish these goals KUCC has four research programs including: Cancer Biology, Cancer Control and Population Health, Cancer Prevention, and Drug Discovery, Delivery and Experimental Therapeutics. In addition, the Cancer Center supports four shared resources: Biostatistics and Informatics, Lead Development and Optimization, Biospecimen, and Clinical Trials Management.

Public Health Relevance

KUCC aims to leverage unique regional scientific assets to build a nationally significant cancer research center that will become a leading institution for transforming discoveries in the laboratory into new therapeutic approaches. We hope to establish an NCI-designated cancer center to meet the needs of the more than five million Americans who live within the 120,000 square miles of our catchment area.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Schools of Medicine
Kansas City
United States
Zip Code
Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438
Lal, Shruti; Cheung, Edwin C; Zarei, Mahsa et al. (2017) CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Mol Cancer Res 15:696-707
Xiao, Lifu; Tian, Xiumei; Harihar, Sitaram et al. (2017) Gd2O3-doped silica @ Au nanoparticles for in vitro imaging cancer biomarkers using surface-enhanced Raman scattering. Spectrochim Acta A Mol Biomol Spectrosc 181:218-225
Pessetto, Ziyan Y; Chen, Bin; Alturkmani, Hani et al. (2017) In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget 8:4079-4095
Wolfe, Andy R; Ernlund, Amanda; McGuinness, William et al. (2017) Suppression of intestinal tumorigenesis in Apc mutant mice upon Musashi-1 deletion. J Cell Sci 130:805-813
Sasaki, Ken; Kurahara, Hiroshi; Young, Eric D et al. (2017) Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. Clin Exp Metastasis 34:229-239
New, Jacob; Arnold, Levi; Ananth, Megha et al. (2017) Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res 77:6679-6691
Brinker, Amanda E; Vivian, Carolyn J; Koestler, Devin C et al. (2017) Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driver-Dependent Manner. Cancer Res 77:6941-6949
Do, Thuy-Vy; Hirst, Jeff; Hyter, Stephen et al. (2017) Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget 8:50376-50392
Spaw, Mark; Anant, Shrikant; Thomas, Sufi Mary (2017) Stromal contributions to the carcinogenic process. Mol Carcinog 56:1199-1213

Showing the most recent 10 out of 135 publications